Overview of Cencora#
William Blair has initiated coverage on Cencora Inc (NYSE:COR) with a Market Perform rating. This means they expect the stock to perform similarly to the overall market. Cencora is recognized as one of the largest global pharmaceutical distributors, which gives it a significant competitive advantage.
Growth Potential#
The firm noted that Cencora's extensive pharmaceutical distribution platform creates a strong competitive moat. This positioning allows the company to benefit from favorable market conditions, including demographic trends, ongoing innovation, and the introduction of new drugs. Additionally, there is an increasing adoption of specialty medicines, which are drugs tailored for specific patient needs.
Recent Acquisition#
In a significant development, Cencora announced its agreement to acquire EyeSouth Partners’ retina business for $1.1 billion. This acquisition will be financed through existing credit facilities and cash reserves. The retina business generated over $600 million in revenue and approximately $75 million in earnings before interest, taxes, depreciation, and amortization (EBITDA) in 2022, indicating strong financial performance.
Analyst Ratings#
Following the acquisition news, several analysts have reiterated their ratings on Cencora stock. UBS maintains a Buy rating with a price target of $410.00, while Evercore ISI has an Outperform rating with a $420.00 target. BofA Securities holds a Neutral rating with a $380.00 target. Additionally, Cencora's CFO, James Cleary, will retire after 7.5 years, and no successor has been announced yet. Following this news, Leerink Partners also reiterated an Outperform rating with a price target of $447.00 for Cencora shares.